Phosphatidylserine-decorated delivery platform helps alleviate acute lung injury via potentiating macrophage targeting

Acute lung injury (ALI) is a life-threatening inflammatory disease with high morbidity and mortality. It is urgent to develop more effective therapeutic strategies against ALI. Phosphatidylserine (PtdSer) expressed on the surface of apoptotic cells not only allows for macrophage binding and recognition but also drives anti-inflammatory signaling within the macrophage. In this study, we designed an apoptotic cell-mimicry nanoparticle by decorating synthetic PtdSer on the outer face of nanoparticles. The results indicated that PtdSer-decorated poly(lactic-co-glycolic acid) nanoparticles (PSNPs) showed anti-inflammatory properties and increased macrophage phagocytosis in relative to the nondecorated poly(lactic-co-glycolic acid nanoparticles. Dexamethasone-loaded PSNPs exhibited superior anti-inflammatory activity on macrophages in vitro. In vivo studies also showed that PtdSer decoration increased the accumulation of nanoparticles in lung macrophages after pulmonary administration. Accumulation of dexamethasone-loaded PSNPs in lung macrophages effectively reduced inflammation in inflamed lungs and further alleviated ALI syndromes. In conclusion, PtdSer decoration not only endows the anti-inflammatory function to nanocarriers but also potentiates its macrophage targeting in the inflamed microenvironment, which offers an ideal drug delivery platform for ALI therapy.

• Publication year

  2025

• Venue

  Journal of Lipid Research

• Publication date

  2025-04-01

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.1016/j.jlr.2025.100799PMID 40216334PMCID 12127575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of phosphatidylserine on the membrane in immunity and blood coagulation

  2022cited by this paper
• Biology of lung macrophages in health and disease.

  2022cited by this paper
• Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management.

  2022cited by this paper
• Drugging the efferocytosis process: concepts and opportunities

  2022cited by this paper
• Macrophage-Targeted Nanomedicines for ARDS/ALI: Promise and Potential

  2022cited by this paper
• Phosphatidylserine enhances anti‐inflammatory effects of reconstituted HDL in macrophages via distinct intracellular pathways

  2022cited by this paper
• The lung surfactant activity probed with molecular dynamics simulations.

  2022cited by this paper
• Acute respiratory distress syndrome

  2021cited by this paper
• Calming Cytokine Storm in Pneumonia by Targeted Delivery of TPCA-1 Using Platelet-Derived Extracellular Vesicles

  2020cited by this paper
• Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties

  2020cited by this paper
• Dexamethasone nanomedicines for COVID-19

  2020cited by this paper
• Macrophage polarization and its role in the pathogenesis of acute lung injury/acute respiratory distress syndrome

  2020cited by this paper
• Blood clots and TAM receptor signalling in COVID-19 pathogenesis

  2020cited by this paper
• The role of phosphatidylserine recognition receptors in multiple biological functions

  2020cited by this paper
• Ligand density on nanoparticles: A parameter with critical impact on nanomedicine.

  2019cited by this paper
• How macrophages deal with death

  2019cited by this paper
• Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation

  2019cited by this paper
• Corticosteroids in Acute Lung Injury: The Dilemma Continues

  2019cited by this paper
• TAM receptors, Phosphatidylserine, inflammation, and Cancer

  2019cited by this paper
• Efferocytosis in health and disease

  2019cited by this paper
• Size effect of curcumin nanocrystals on dissolution, airway mucosa penetration, lung tissue distribution and absorption by pulmonary delivery.

  2019cited by this paper
• Regulatory T Cells and Acute Lung Injury: Cytokines, Uncontrolled Inflammation, and Therapeutic Implications

  2018cited by this paper
• Inhalation therapies in acute respiratory distress syndrome.

  2017cited by this paper
• High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy.

  2017cited by this paper
• Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis

  2016cited by this paper
• Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages

  2015cited by this paper
• Chitosan-coated PLGA nanoparticles: a sustained drug release strategy for cell cultures.

  2013cited by this paper
• Dissolution Techniques for In Vitro Testing of Dry Powders for Inhalation

  2012influential reference
• Defective phagocytosis in airways disease.

  2012cited by this paper
• An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals.

  2011cited by this paper
• Lipopolysaccharide inhibits macrophage phagocytosis of apoptotic neutrophils by regulating the production of tumour necrosis factor α and growth arrest‐specific gene 6

  2011cited by this paper
• Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair

  2011cited by this paper
• Acute Lung Injury: Epidemiology, Pathogenesis, and Treatment

  2010cited by this paper
• Apoptotic mimicry: phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator‐activated receptors (PPARs) in vivo

  2007cited by this paper
• G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method.

  2006cited by this paper
• A novel method for assessing dissolution of aerosol inhaler products.

  2003cited by this paper
• Cytokine-mediated inflammation in acute lung injury.

  2003cited by this paper
• Lipopolysaccharide-induced suppression of phagocytosis: effects on the phagocytic machinery.

  1996cited by this paper
• Lipopolysaccharide‐induced suppression of erythrocyte binding and phagocytosis via FCγRI, FCγRII, FCγRIII, and CR3 receptors in murine macrophages

  1993cited by this paper

• A state-of-the-art review on inhalable nanoconjugates for targeted drug delivery in acute lung injury: Advances, challenges and future directions.

  2025cites this paper
• Macrophage efferocytosis: Mechanisms and therapeutic opportunities for future cardiovascular diseases.

  2025cites this paper